1. Home
  2. DCTH vs IPSC Comparison

DCTH vs IPSC Comparison

Compare DCTH & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.11

Market Cap

363.5M

Sector

Health Care

ML Signal

HOLD

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

413.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
IPSC
Founded
1988
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
363.5M
413.0M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
DCTH
IPSC
Price
$11.11
$2.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$22.00
$4.25
AVG Volume (30 Days)
378.1K
739.4K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
107.53
91.30
EPS
N/A
N/A
Revenue
N/A
$109,164,000.00
Revenue This Year
$24.54
N/A
Revenue Next Year
$33.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1556.76
52 Week Low
$8.12
$0.44
52 Week High
$18.23
$2.97

Technical Indicators

Market Signals
Indicator
DCTH
IPSC
Relative Strength Index (RSI) 53.27 52.10
Support Level $10.17 $2.15
Resistance Level $11.24 $2.42
Average True Range (ATR) 0.56 0.12
MACD -0.02 0.00
Stochastic Oscillator 46.85 74.00

Price Performance

Historical Comparison
DCTH
IPSC

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Share on Social Networks: